Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 7, 2014

Merck Announces Management Changes

Author(s)Melanie Sena

Merck promotes internal managers to head Merck Millipore and Consumer Health Divisions.

Merck KGaA

reported the promotion of three internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit as part of its “Fit for 2018” program.

Udit Batra, who previously managed Consumer Health, will become president and CEO of the Life Science Tools division, succeeding Robert Yates, who has left the company. Uta Kemmerich-Keil, currently CEO of Allergopharma and head of the global allergy business unit, will succeed Batra in his role as president and CEO of Consumer Health. Kemmerich-Keil will be replaced at Allergopharma by Marco Linari, who was head of the Operating Model within Merck Millipore and Performance Materials. All changes will take effect May 15.

In addition, Merck Serono President and CEO Belén Garijo will take charge of the R&D organization ad interim while the search for a permanent leader for the R&D organization is conducted. Annalisa Jenkins, who served in that role, left the company at the end of March.

Source:

Merck KGaA


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.